Видео ютуба по тегу Resistant Cml

Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
Emerging therapeutic approaches for TKI-resistant CML
Emerging therapeutic approaches for TKI-resistant CML
Targeting TKI-resistant CML with LY3009120 and asciminib
Targeting TKI-resistant CML with LY3009120 and asciminib
Resistant Chronic Myeloid Leukemia
Resistant Chronic Myeloid Leukemia
Addressing the issue of resistance to TKIs in CML
Addressing the issue of resistance to TKIs in CML
Alternative Mechanism for Treatment of Resistant CML
Alternative Mechanism for Treatment of Resistant CML
An update on a Phase II study of fedratinib in MDS/MPN overlaps and chronic neutrophilic leukemia
An update on a Phase II study of fedratinib in MDS/MPN overlaps and chronic neutrophilic leukemia
Mechanisms of resistance to the TKI asciminib in CML
Mechanisms of resistance to the TKI asciminib in CML
Outcomes of patients with CML with no molecular response within two years of TKI therapy
Outcomes of patients with CML with no molecular response within two years of TKI therapy
OPTIC: ponatinib in resistant chronic-phase CML
OPTIC: ponatinib in resistant chronic-phase CML
Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
Experience with Omacetaxine for TKI-Resistant TKI CML
Experience with Omacetaxine for TKI-Resistant TKI CML
Chronic Myeloid Leukemia -2023 Best of Hematology Conference
Chronic Myeloid Leukemia -2023 Best of Hematology Conference
Novel treatment strategies for patients with CML who are intolerant or resistant to available TKIs
Novel treatment strategies for patients with CML who are intolerant or resistant to available TKIs
Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental Therapy
Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental Therapy
Managing drug resistance in CP-CML with ponatinib and asciminib
Managing drug resistance in CP-CML with ponatinib and asciminib
When can TKIs be stopped in CML?
When can TKIs be stopped in CML?
Asciminib: overcoming TKI resistance and reducing toxicity in CML
Asciminib: overcoming TKI resistance and reducing toxicity in CML
Unmet needs in CML: life-threatening toxicities, QoL & dealing with intolerance and resistance
Unmet needs in CML: life-threatening toxicities, QoL & dealing with intolerance and resistance
Unmet needs in CML: dealing with resistance and progression, pregnancy, QoL & access to treatment
Unmet needs in CML: dealing with resistance and progression, pregnancy, QoL & access to treatment